Substance (Drug) Abuse Drug Pipeline Analysis Report 2024

Report Coverage

The Substance (Drug) Abuse Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into substance (drug) abuse drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for substance (drug) abuse. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The substance (drug) abuse pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from substance (drug) abuse.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to substance (drug) abuse.

Substance (Drug) Abuse Drug Pipeline Outlook

Substance (drug) abuse includes a pattern of excessive use of psychoactive drugs that can lead to physical, emotional, or social harm. Drug abuse involves both psychological and physical dependence on drugs such as pain medications or alcohol. Genetic predisposition and environmental factors can increase a person’s risk of addiction. Additionally, people with mental health disorders and teenagers are more prone to drug use and addiction compared to other populations.

Medication along with some type of behavioral therapy or counseling is considered the first line of treatment for people suffering from opioid addiction. Common medications include methadone, buprenorphine, extended-release naltrexone, and lofexidine which help in treating opioid drug addiction and withdrawal. With increasing funding and support for addiction research and treatment programs from governmental and non-governmental organizations, the substance (drug) abuse pipeline is anticipated to witness a steady expansion in the coming years.

Substance (Drug) Abuse – Drug Pipeline Therapeutic Assessment

Substance (Drug) Abuse – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I and II cover a major share of the total clinical trials for substance (drug) abuse.

Substance (Drug) Abuse – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the substance (drug) abuse pipeline analysis include small molecule, biologics, peptide, monoclonal antibody, and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for substance (drug) abuse.

Substance (Drug) Abuse Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the substance (drug) abuse drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in substance (drug) abuse clinical trials:

• Tonix Pharmaceuticals, Inc.
• Tempero Bio, Inc.
• Power Life Sciences Inc.
• Tris Pharma, Inc.
• Aelis Farma
• Wecare Probiotics Co., Ltd.
• Theranova, L.L.C.
• Inventage Lab., Inc.

Substance (Drug) Abuse – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: TMP-301

Sponsored by Tempero Bio, Inc., the objective of this participant-blinded, placebo-controlled Phase II study is to assess the preliminary efficacy, tolerability, and safety of TMP-301 in around 100 adult patients with alcohol use disorder (AUD).

Drug: Probenecid

This Phase II clinical trial is aimed at investigating the use of the drug probenecid in alleviating the sympt...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Reasons To Buy This Report

The Substance (Drug) Abuse Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for substance (drug) abuse. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within substance (drug) abuse pipeline insights.

Key Questions Answered in the Substance (Drug) Abuse – Pipeline Insight Report

• What is the current landscape of substance (drug) abuse pipeline drugs?
• How many companies are developing Substance (Drug) Abuse drugs?
• How many phase III and phase IV drugs are currently present in substance (drug) abuse pipeline drugs?
• Which companies/institutions are leading the substance (drug) abuse drug development?
• What is the efficacy and safety profile of substance (drug) abuse pipeline drugs?
• What are the opportunities and challenges present in the substance (drug) abuse drug pipeline landscape?
• Which company is conducting major trials for substance (drug) abuse drugs?
• What geographies are covered for substance (drug) abuse clinical trials?
• What are emerging trends in substance (drug) abuse clinical trials?

Related Reports

Substance Drug Abuse Market Report

Global Clinical Trials Market